Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Effect of the oral vasopressin receptor antagonist tolvaptan on congestive cardiac failure in a child with restrictive cardiomyopathy.

Horibata Y, Murakami T, Niwa K.

Cardiol Young. 2014 Feb;24(1):155-7. doi: 10.1017/S1047951112002272. Epub 2013 Feb 6.

PMID:
23388069
2.

Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.

Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T.

Cardiovasc Drug Rev. 2007 Spring;25(1):1-13. Review.

PMID:
17445084
3.

Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure.

Rangasetty UC, Gheorghiade M, Uretsky BF, Orlandi C, Barbagelata A.

Expert Opin Investig Drugs. 2006 May;15(5):533-40. Review.

PMID:
16634691
4.

Tolvaptan, an oral vasopressin V2 receptor antagonist for heart failure?

Greenberg A.

Am J Kidney Dis. 2007 Dec;50(6):904-7. No abstract available.

PMID:
18037090
5.

Tolvaptan (Otsuka).

Doggrell SA.

Curr Opin Investig Drugs. 2004 Sep;5(9):977-83. Review.

PMID:
15503654
6.

The therapeutic potential of vasopressin receptor antagonists in congestive heart failure.

Salam AM.

Expert Opin Investig Drugs. 2005 May;14(5):687-91.

PMID:
15926874
7.

Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.

Veeraveedu PT, Watanabe K, Ma M, Palaniyandi SS, Yamaguchi K, Kodama M, Aizawa Y.

Biochem Pharmacol. 2008 Mar 15;75(6):1322-30. doi: 10.1016/j.bcp.2007.11.011. Epub 2007 Dec 3.

PMID:
18179782
8.

Preliminary report of tolvaptan treatment in Japanese patients with heart failure.

Semba H, Kinugawa K, Takeda N, Shiga T, Nishimura G, Inajima T, Uchino Y, Iwata H, Hasumi E, Abe H, Terada Y, Yonenaga A, Hirata Y, Nagai R.

Int Heart J. 2012;53(1):72-4.

9.

Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials.

Pang PS, Gheorghiade M, Dihu J, Swedberg K, Khan S, Maggioni AP, Grinfeld L, Zannad F, Burnett JC Jr, Ouyang J, Udelson JE, Konstam MA.

Am Heart J. 2011 Jun;161(6):1067-72. doi: 10.1016/j.ahj.2011.02.027.

PMID:
21641352
10.

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.

Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C; Tolvaptan Investigators.

Circulation. 2003 Jun 3;107(21):2690-6. Epub 2003 May 12.

11.

Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.

Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, O'Brien T, Kronenberg MW, Zimmer C, Orlandi C, Konstam MA.

J Am Coll Cardiol. 2007 Jun 5;49(22):2151-9. Epub 2007 May 18.

12.

Renoprotective effect of vasopressin v2 receptor antagonist tolvaptan in Dahl rats with end-stage heart failure.

Ishikawa M, Kobayashi N, Sugiyama F, Onoda S, Ishimitsu T.

Int Heart J. 2013;54(2):98-106.

13.

Vasopressin antagonists in heart failure.

Golestaneh L, Talreja A, Le Jemtel TH.

Curr Heart Fail Rep. 2004 Dec;1(4):190-6. Review.

PMID:
16036044
14.

Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).

Gheorghiade M, Orlandi C, Burnett JC, Demets D, Grinfeld L, Maggioni A, Swedberg K, Udelson JE, Zannad F, Zimmer C, Konstam MA.

J Card Fail. 2005 May;11(4):260-9.

PMID:
15880334
15.

Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure.

Hauptman PJ, Zimmer C, Udelson J, Shoaf SE, Mallikaarjun S, Bramer SL, Orlandi C.

J Cardiovasc Pharmacol. 2005 Nov;46(5):609-14.

PMID:
16220067
16.

[Vasopressin V2-receptor antagonist, tolvaptan, for treatment of heart failure].

Yamamura Y, Sato O, Fujiki H.

Nihon Rinsho. 2007 May 28;65 Suppl 5:164-8. Review. Japanese. No abstract available.

PMID:
17571379
17.

V2 receptor antagonism with tolvaptan in heart failure.

Costello-Boerrigter LC, Boerrigter G, Burnett JC Jr.

Expert Opin Investig Drugs. 2007 Oct;16(10):1639-47. Review.

PMID:
17922627
18.

Tolvaptan for the treatment of hyponatremia and hypervolemia in patients with congestive heart failure.

Hori M.

Future Cardiol. 2013 Mar;9(2):163-76. doi: 10.2217/fca.13.3.

PMID:
23463968
19.

Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients.

Kinugawa K, Imamura T, Komuro I.

Clin Pharmacol Ther. 2013 Oct;94(4):449-51. doi: 10.1038/clpt.2013.147. Epub 2013 Jul 19. No abstract available.

PMID:
23872863
20.

Effects of tolvaptan on congestive heart failure complicated with chylothorax in a neonate.

Sato N, Sugiura T, Nagasaki R, Suzuki K, Ito K, Kato T, Inukai S, Saitoh S.

Pediatr Int. 2015 Oct;57(5):1020-2. doi: 10.1111/ped.12697. Epub 2015 Sep 10.

PMID:
26508187

Supplemental Content

Support Center